•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Yahoo
66.67%
Finnhub
33.33%
Country
US
Industry
Health Care
Market Cap
Micro Cap
Num. Employees
105
IPO Date
Oct 9, 2020
Country
US
Industry
Health Care
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 105 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. SL-172154 is in an ongoing Phase I clinical trial for the treatment of patients with ovarian cancer. The company is also evaluating SL-172154 in an ongoing Phase I clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia (AML), and higher-risk myelodysplastic syndromes (HR-MDS). The firm is also advancing a Gamma Delta T Cell Engager, GADLEN platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.
Taylor Schreiber, M.D., Ph.D., CEO of Shattuck Labs will participate in a presentation on December 3, 2024.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with STTK
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data